Glucagon-like peptide-1 : New target for treating non-alcoholic fatty liver disease?
10.3760/cma.j.issn.1000-6699.2015.05.002
- VernacularTitle:胰升糖素样肽1:非酒精性脂肪性肝病治疗的新靶点?
- Author:
Ye LIU
;
Tianpei HONG
;
Rui WEI
;
Jin YANG
- Publication Type:Journal Article
- Keywords:
Non-alcoholic fatty liver disease;
Glucagon-like peptide-1;
Dipeptidyl peptidase-4
- From:
Chinese Journal of Endocrinology and Metabolism
2015;31(5):386-389
- CountryChina
- Language:Chinese
-
Abstract:
Recent studies have demonstrated an association of glucagon-like peptide-1 (GLP-1) signaling defect with non-alcoholic fatty liver disease (NAFLD).Native GLP-1 and GLP-1-based agents may directly act on hepatocytes through activation of GLP-1 receptors in hepatocytes,resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism,and the suppression of oxidative stress in liver cells.Moreover,GLP-1-based agents have been reported to be effective in improving hepatic endpoints in patients with NAFLD.
